| Title: |
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer |
| Authors: |
Beltran, Himisha; Calais, Jeremie; Emmett, Louise; Kuo, Phillip H.; Logothetis, Christopher J. |
| Contributors: |
Novartis Pharmaceuticals Corporation |
| Source: |
Frontiers in Oncology ; volume 15 ; ISSN 2234-943X |
| Publisher Information: |
Frontiers Media SA |
| Publication Year: |
2025 |
| Collection: |
Frontiers (Publisher - via CrossRef) |
| Description: |
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [ 177 Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [ 177 Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [ 177 Lu]Lu-PSMA-617 and guide therapy decision-making. This review explores the landscape of emerging clinical, molecular, and imaging biomarkers, and their potential utility as prognostic and/or predictive biomarkers in the context of [ 177 Lu]Lu-PSMA-617 treatment for patients with mCRPC. |
| Document Type: |
article in journal/newspaper |
| Language: |
unknown |
| DOI: |
10.3389/fonc.2025.1583168 |
| DOI: |
10.3389/fonc.2025.1583168/full |
| Availability: |
https://doi.org/10.3389/fonc.2025.1583168; https://www.frontiersin.org/articles/10.3389/fonc.2025.1583168/full |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.535F409B |
| Database: |
BASE |